Literature DB >> 11264590

Expression, purification and preliminary crystallographic studies of human ketohexokinase.

M Kozak1, B Hayward, D Borek, D T Bonthron, M Jaskólski.   

Abstract

Ketohexokinase (KHK; E.C. 2.7.1.3) catalyses the (reversible) phosphorylation of fructose to fructose-1-phosphate. KHK is the first enzyme in a specialized catabolic pathway metabolizing dietary fructose to the glycolytic intermediate glyceraldehyde-3-phosphate. Mutations inactivating KHK underlie the metabolic disorder essential fructosuria. The primary structure of KHK shows no significant homology to other mammalian hexokinases. It is most similar to prokaryotic ribokinases, but catalyses a distinct phosphorylation reaction. Recombinant human KHK has been crystallized in the orthorhombic form (space group P2(1)2(1)2 or P2(1)2(1)2(1)). Single crystals of this polymorph suitable for X-ray diffraction have been obtained by vapour diffusion using 2-propanol and MPD as precipitants (pH 7.5). The crystals have unit-cell parameters a = 93.4, b = 121.5, c = 108.4 A. Diffraction data were collected to 4.3 A resolution. The asymmetric unit contains four protein molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264590     DOI: 10.1107/s0907444901001007

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  2 in total

1.  Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.

Authors:  Bruce E Maryanoff; John C O'Neill; David F McComsey; Stephen C Yabut; Diane K Luci; Alfonzo D Jordan; John A Masucci; William J Jones; Marta C Abad; Alan C Gibbs; Ioanna Petrounia
Journal:  ACS Med Chem Lett       Date:  2011-04-18       Impact factor: 4.345

2.  Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells.

Authors:  Pietro Cirillo; Michael S Gersch; Wei Mu; Philip M Scherer; Kyung Mee Kim; Loreto Gesualdo; George N Henderson; Richard J Johnson; Yuri Y Sautin
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.